Boston, MA 10/09/2014 (wallstreetpr) – Cardinal Health Inc (NYSE:CAH) has completed a five-year project that it had taken up in collaboration with the Ohio State University and State of Ohio Third Frontier Commission.
A MarketWatch article highlighted the achievement of the Dublin, Ohio headquartered company. The news stated that the project aimed at creating a new, $13 million molecular imaging pharmaceutical center. The program intends to better the future of the medical diagnostic industry.
Future Outlook
The center is named Translational Research Center for Molecular Imaging Pharmaceuticals. It is a state-of-the-art facility at the Ohio State’s Wright Center of Innovation in Biomedical Imaging where it occupies an area of 27,000 square foot. It integrates the research capabilities of the Ohio State’s Center with Cardinal Health’s expertise in molecular imaging agents. Cardinal Health Inc (NYSE:CAH) specializes in various operations of the sector including manufacturing, development and commercialization.
The chief task of the new facility is to research and develop specialized pharmaceutical components called “imaging agents.” These components are injected inside the body, and they discover specific cellular functions, which indicate particular disease processes. The imaging agents can be viewed with the aid of advanced imaging equipment and can provide a significant contribution in the diagnosis, as well as treatment of diseases. They are capable of helping in diagnosing and treating diseases such as neurological or cardiovascular disorders and also cancer.
Aid For Research & Development
Situated on Ohio State’s west campus facility, the new center has been located such that it is completely integrated with Ohio State’s chief infrastructure. It employs over 80 people, comprising of researchers from Ohio State and Cardinal Health’s personnel from the nuclear pharmacy division and radiopharmaceutical manufacturing operations.
The molecular imaging technology facility aims at providing researchers at Ohio State unique manufacturing provisions. Expertise and assistance in their research will also be available at their disposal. Cardinal Health will support the development and manufacturing as also the dispensing, for clinical drug studies in Ohio.
